Bhi Skin

Berberis Vulgaris Root Bark, Graphite, Hydrofluoric Acid, Lycopodium Clavatum Spore, Petrolatum, Toxicodendron Pubescens Leaf, Sepia Officinalis Juice, And Sulfur


Medinatura Inc
Human Otc Drug
NDC 62795-1016
Bhi Skin also known as Berberis Vulgaris Root Bark, Graphite, Hydrofluoric Acid, Lycopodium Clavatum Spore, Petrolatum, Toxicodendron Pubescens Leaf, Sepia Officinalis Juice, And Sulfur is a human otc drug labeled by 'Medinatura Inc'. National Drug Code (NDC) number for Bhi Skin is 62795-1016. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Bhi Skin drug includes Berberis Vulgaris Root Bark - 6 [hp_X]/1 Graphite - 10 [hp_X]/1 Hydrofluoric Acid - 10 [hp_X]/1 Lycopodium Clavatum Spore - 12 [hp_X]/1 Petrolatum - 10 [hp_X]/1 Sepia Officinalis Juice - 10 [hp_X]/1 Sulfur - 12 [hp_X]/1 Toxicodendron Pubescens Leaf - 8 [hp_X]/1 . The currest status of Bhi Skin drug is Active.

Drug Information:

Drug NDC: 62795-1016
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Bhi Skin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Berberis Vulgaris Root Bark, Graphite, Hydrofluoric Acid, Lycopodium Clavatum Spore, Petrolatum, Toxicodendron Pubescens Leaf, Sepia Officinalis Juice, And Sulfur
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medinatura Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BERBERIS VULGARIS ROOT BARK - 6 [hp_X]/1
GRAPHITE - 10 [hp_X]/1
HYDROFLUORIC ACID - 10 [hp_X]/1
LYCOPODIUM CLAVATUM SPORE - 12 [hp_X]/1
PETROLATUM - 10 [hp_X]/1
SEPIA OFFICINALIS JUICE - 10 [hp_X]/1
SULFUR - 12 [hp_X]/1
TOXICODENDRON PUBESCENS LEAF - 8 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:MediNatura Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:1TH8Q20J0U
4QQN74LH4O
RGL5YE86CZ
C88X29Y479
4T6H12BN9U
QDL83WN8C2
70FD1KFU70
6IO182RP7A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62795-1016-31 PACKAGE in 1 CARTON (62795-1016-3) / 100 TABLET in 1 PACKAGE01 Jan, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose eczema relief tablets relieves: • rough scaly skin • itching skin • redness

Product Elements:

Bhi skin berberis vulgaris root bark, graphite, hydrofluoric acid, lycopodium clavatum spore, petrolatum, toxicodendron pubescens leaf, sepia officinalis juice, and sulfur berberis vulgaris root bark berberis vulgaris root bark graphite graphite hydrofluoric acid fluoride ion lycopodium clavatum spore lycopodium clavatum spore petrolatum petrolatum toxicodendron pubescens leaf toxicodendron pubescens leaf sepia officinalis juice sepia officinalis juice sulfur sulfur magnesium stearate maltodextrin dextrose leafman

Indications and Usage:

Uses for the temporary relief of minor eczema symptoms: rough scaly skin, itching skin, redness

Warnings:

Warnings section if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. if symptoms persist or worsen, a health professional should be consulted. do not use if known sensitivity to bhi skin or any of its ingredients exists.

Dosage and Administration:

Directions at first sign of symptoms: adults and children 4 years and older: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. standard dosage: adults and children 4 years and older: take 1-2 tablet every 4 to 6 hours. do not exceed 12 tablets in 24 hours. for children under 4, consult your health professional. allow tablets to dissolve completely in the mouth, do not swallow.

Package Label Principal Display Panel:

Add image transcription here... bhi skin tablet


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.